AbbVie : ABBV

All AbbVie Articles

616 Articles

Chris Lange | Sep 7, 2017 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a mixed day for the U.S. broad markets with all major indices starting off positive, but quickly souring…

Chris Lange | Aug 25, 2017 at 9:55 AM EDT

Short Sellers Run for Cover From Major Pharma

The August 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Aug 10, 2017 at 8:40 AM EDT

Short Sellers Hike Bets in Major Pharma

The July 31 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Aug 2, 2017 at 1:20 PM EDT

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its…

Chris Lange | Jul 28, 2017 at 11:10 AM EDT

AbbVie Slips Despite Q2 Earnings Beat

AbbVie reported better-than-expected second-quarter financial results before the markets opened on Friday.

Chris Lange | Jul 26, 2017 at 8:55 AM EDT

Major Pharma Short Interest Takes a Big Step Back

The July 14 short interest data have been compared with the previous figures, and short interest in most of these…

Lee Jackson | Jul 19, 2017 at 9:42 AM EDT

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

A new report from SunTrust Robinson Humphrey indicates big pharmaceuticals may be the place to be for investors. Among the…

Chris Lange | Jul 13, 2017 at 9:20 AM EDT

Major Pharma Short Sellers Become More Selective

The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jun 12, 2017 at 8:55 AM EDT

Short Sellers Grow More Selective on Major Pharma

The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 2, 2017 at 1:35 PM EDT

15 Companies Bracing for Big ASCO Reactions

24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could…

Chris Lange | May 27, 2017 at 8:40 AM EDT

Big Pharma Has Big Catalysts Coming for the Rest of 2017

A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow…

Chris Lange | May 25, 2017 at 9:45 AM EDT

Major Pharma Short Interest Surges

The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | May 17, 2017 at 12:10 PM EDT

Why This Humira Patent Loss Might Not Be What You Think

AbbVie watched its shares slide on Wednesday following a ruling from the U.S. Patent and Trade Mark Office's Trial and…

1 … 25 26 27 28 29 … 42

AbbVie : ABBV

All AbbVie Articles

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Run for Cover From Major Pharma

Short Sellers Hike Bets in Major Pharma

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

AbbVie Slips Despite Q2 Earnings Beat

Major Pharma Short Interest Takes a Big Step Back

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Why This Humira Patent Loss Might Not Be What You Think

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

SpaceX Just Erased $1 Trillion in Value. Here’s Why the Worst Could Be Yet to Come.

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

AbbVie : ABBV

All AbbVie Articles

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Run for Cover From Major Pharma

Short Sellers Hike Bets in Major Pharma

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

AbbVie Slips Despite Q2 Earnings Beat

Major Pharma Short Interest Takes a Big Step Back

SunTrust Says Big Pharmaceuticals Have Multiple Catalysts for the Rest of 2017

Major Pharma Short Sellers Become More Selective

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

Why This Humira Patent Loss Might Not Be What You Think

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

SpaceX Just Erased $1 Trillion in Value. Here’s Why the Worst Could Be Yet to Come.

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account